Amarin Corp Plc (AMRN)

[sharinky]

Thanks to John Cappello and others for engaging Dr. Deepak Bhatt in great twitter conversations.


Dr. Deepak L. Bhatt
?

@DLBHATTMD
10h10 hours ago
More
Replying to @JrwilliWilliams @JohnCappello @DrDerekConnolly
Given how well icosapent ethyl performed in patients with diabetes, metabolic syndrome would be an appealing population for a next trial. Not sure a head to head trial would be feasible given current pricing of PCSK9 inhibitors though.
0 replies 0 retweets 4 likes
Reply Retweet Liked 4 Direct message

Dr. Deepak L. Bhatt
?

@DLBHATTMD
14h14 hours ago
More
Replying to @ra_fun @DrDerekConnolly
I view statins (LDL reduction) and icosapent ethyl (multiple mechanisms of benefit) as complementary approaches. However, if a patient cannot take statins due to side effects, I would not deny them icosapent ethyl, even though we did not study that. A combo pill seems brilliant.
0 replies 6 retweets 30 likes
Reply Retweet 6 Liked 30 Direct message

Dr. Deepak L. Bhatt
?

@DLBHATTMD
14h14 hours ago
More
Replying to @JohnCappello @DrDerekConnolly
While icosapent ethyl is a prescription drug and a highly purified ethyl ester of EPA, it is ultimately derived from nature. As such, I believe it has multiple therapeutic effects. Probably a Nobel prize in there for a basic scientist who can unravel exactly via what mechanisms.
1 reply 1 retweet 12 likes
Reply 1 Retweet 1 Liked 12 Direct message